Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Humana Inc (H1UM34) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Humana Inc BRL 16.81, price BRL 44.28, upside -62.0%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
HI
Broad data
Sep 29, 2026
Humana Inc
H1UM34 · SAStretched ValuationStrong overvaluation with only moderate quality.
!Fair value R$16.81 · Strongly overvalued (−62.0%)
!Quality 55/100
!Mixed Growth (revenue 3y +11.8 %/yr)
!Thin margins · 0.8% net margin (TTM)
✓Moderate debt · generates free cash flow
!8.0% dividend yield · Watch coverage
!Narrow moat 32/100
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
How to read this chart
60‑month range R$19.00 – R$64.12 · fair‑value band R$7.76 – R$27.11 · the R$44.28 price screens above the R$16.81 fair value. Dashed = 300-day average. As of Sep 29, 2026.
Company profile
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell.
Show more
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Stock analysis
Humana Inc (H1UM34) currently trades at R$44.28, while our model-based Fair Value estimate is R$16.81, 62.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of R$24.11 per share, and 0 of the 25 models we run sit above the R$44.28 price.
Bear case: the Dividend Discount group reads lowest at R$6.69, and 25 of the 25 models stay below the price. Evidence for this calculation is high.
Scenario range: R$7.76 (bear) to R$27.11 (bull), the price of R$44.28 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Humana Inc reported revenue of $130B in FY2025 versus $83.1B in FY2021, a compound +11.8%/yr. Reported net income was $1.2B in FY2025, compounding −20.2%/yr from FY2021.
Key figures
Market cap R$251B (≈ $48.1B) · P/E ratio 41.0 · P/S ratio 0.38 · EPS (TTM) R$1.08 · Dividend yield 8.0% · Net margin 0.9% · Return on equity 6.3% · Return on assets (EBIT) 7.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 7% below its 52-week high and 133% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 16% fair-value upside, at −62%, H1UM34 screens richer than that median.
Fair Value models
Bear R$7.76
Fair Value R$16.81
Bull R$27.11
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income
R$13.75
R$14.40
R$15.80
73
EPV
R$11.28
R$14.48
R$17.27
71
FCF DCF
R$2.80
R$11.05
R$25.16
69
All 25 models by family
DCF Models
FCF DCF
R$2.80
R$11.05
R$25.16
69
Owner Earnings
R$15.53
R$33.61
R$64.52
69
5Y Revenue Exit
R$10.98
R$27.53
R$50.22
65
5Y EBITDA Exit
R$15.50
R$36.71
R$63.44
68
5Y P/E Exit
R$6.78
R$18.99
R$32.87
64
10Y Revenue Exit
R$7.32
R$22.09
R$45.05
59
10Y EBITDA Exit
R$11.08
R$28.77
R$55.97
61
10Y P/E Exit
R$5.33
R$15.89
R$30.71
57
Earnings-Based
Graham-Dodd
R$7.81
R$34.54
R$47.29
61
Lynch FV
R$8.95
R$12.78
R$16.62
58
PEG = 1.0
R$8.95
R$12.78
R$16.62
55
EPV
R$11.28
R$14.48
R$17.27
71
Dividend Discount
Gordon GGM
R$3.82
R$7.93
R$12.59
63
DDM Multi-Stage
R$3.82
R$6.69
R$8.33
64
Multiples
P/E Multiple
R$18.09
R$24.11
R$30.14
63
P/S Multiple
R$14.64
R$19.52
R$24.40
58
P/B Multiple
R$14.64
R$19.52
R$24.40
55
EV/EBIT
R$24.60
R$35.44
R$46.27
65
EV/EBITDA
R$24.24
R$34.95
R$45.67
67
EV/Revenue
R$15.30
R$25.24
R$35.18
52
Asset-Based
NCAV (Graham)
R$8.53
R$11.44
R$17.07
54
Growth DCF
Growth DCF
R$2.76
R$10.44
R$23.28
67
Economic Profit
Residual Income
R$13.75
R$14.40
R$15.80
73
ROIC Compounder
R$11.28
R$14.48
R$17.57
69
Growth Earnings
Growth-Adj P/E
R$14.70
R$21.00
R$27.29
65
Notify me when H1UM34 reaches fair value
Put H1UM34 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
55/100
Of which business quality 51 · Market factors (momentum, volatility) 71
Profitability
45
Margins and returns on capital today
Quality Growth
66
Are margins and returns improving?
Cashflow
16
Earnings quality: real cash, not paper profit
Fin. Strength
42
Balance sheet, leverage, solvency risk
Investment
85
Disciplined investing over empire-building
Low Volatility
48
Calm price path (market factor)
Momentum
78
Price trend over the last 3–12 months (market factor)
52W Momentum
87
Distance to the 52-week high (market factor)
Net Issuance
88
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
71/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−7.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−15.4%
Dividend (yield on the price)8.0%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 2%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +14.8% a year for the price and +5.5% for the forecasts.
Forecast 2026 (sales)+25.2%
Forecast 2027 (sales)+4.6%
Projected 2028 (sales)+4.3%
Projected 2029 (sales)+3.9%
Projected 2030 (sales)+3.6%
H1UM34 screens overvalued: fair value 62% below the price. Compare with UnitedHealth Group →
Compare Humana Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Healthcare Plans stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| UnitedHealth Group UNH | $367.08 | $295.49 | −20% |
| CVS Health Corporation CVS | $85.69 | $42.44 | −50% |
| Elevance Health, Inc ELV | $388.82 | $465.08 | +20% |
| The Cigna Group CI | $271.83 | $495.96 | +82% |
| Molina Healthcare, Inc MOH | $189.10 | $219.06 | +16% |
| Oscar Health, Inc OSCR | $29.60 | $59.20 | +100% |
| Progyny, Inc PGNY | $25.19 | $35.44 | +41% |
| Alignment Healthcare, Inc ALHC | $8.21 | $7.45 | −9% |
| Medi Assist Healthcare Services Limited MEDIASSIST | ₹298.50 | ₹226.12 | −24% |
| Healthconn Corp 6665 | 17.00 TWD | 13.18 TWD | −22% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Humana Inc (H1UM34) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of R$16.81 versus a price of R$44.28, about −62% upside (overvalued).
What is the fair value of H1UM34?
Our model-based fair value for Humana Inc is R$16.81 (as of Sep 29, 2026), built from audited fundamentals. The current price: R$44.28.
What is the quality score of H1UM34?
Humana Inc has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Humana Inc (H1UM34)?
Our model-based price target is the fair value of R$16.81 (as of Sep 29, 2026) from 25 valuation models. Cautious scenario R$7.76, optimistic scenario R$27.11. It is a calculation from audited fundamentals, not an analyst target.
What is the Humana Inc stock forecast for 2026?
Our models put fair value at R$16.81, about −62% upside versus a price of R$44.28 (overvalued). Cautious scenario R$7.76, optimistic scenario R$27.11. The calculation is refreshed regularly with new filings.
What is the revenue of Humana Inc (H1UM34)?
Humana Inc reported trailing-twelve-month revenue of about $137B (latest available figure, as of Sep 29, 2026).
Does Humana Inc pay a dividend?
Humana Inc currently shows a dividend yield of about 7.99% relative to its recent price (as of Sep 29, 2026).
What growth is priced into Humana Inc (H1UM34)?
For today's price to be fair in a discounted-cash-flow model, Humana Inc would have to grow free cash flow by +17.5 % per year for five years (discount rate 11.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +11.8 % per year. As of Sep 29, 2026.
What discount rate (WACC) does the fair value of H1UM34 use?
Our models discount Humana Inc at 11.4 %: a base by market capitalisation (large), damped by beta 0.72, country premium for Brazil. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Humana Inc that is +17.5 % per year a year over ten years, using the same discount rate (11.4 %) and the same formula as our fair value.
How much growth has Humana Inc (H1UM34) delivered so far?
Over the past 4 years revenue at Humana Inc grew +11.8 % a year. The price currently implies +17.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Humana Inc (H1UM34) growing?
The median revenue growth in the sector is +2.9 % a year. That is the yardstick for the growth priced into Humana Inc (+17.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Humana Inc (H1UM34)?
The free-cash-flow yield on the price is 36.67 %: that much free cash flow Humana Inc produces per unit of market value. When it exceeds the discount rate of our models (11.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Humana Inc (H1UM34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Humana Inc it is R$16.81 per share (as of Sep 29, 2026), against a price of R$44.28. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Humana Inc stock overvalued or undervalued in 2026?
As of Sep 29, 2026, H1UM34 trades above its calculated fair value: price R$44.28, fair value R$16.81, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of H1UM34?
No. The price is what the market pays today (R$44.28); the fair value is what the company's own numbers justify (R$16.81). For Humana Inc the two are R$27.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Humana Inc worth?
The market values Humana Inc at about R$251B (market capitalisation, as of Sep 29, 2026). Per share that is R$44.28; our models calculate a fair value of R$16.81 per share.
What do the bullish and bearish scenarios say about H1UM34?
Our models span a range for Humana Inc: cautious scenario R$7.76, base R$16.81, optimistic R$27.11 per share (as of Sep 29, 2026, price R$44.28). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is H1UM34 from its 52-week high?
Humana Inc trades at R$44.28, about 7% below its 52-week high of R$47.37 and 133% above the low of R$19.00 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of R$16.81 is for.
Which stocks are comparable to Humana Inc?
From the same area (Healthcare) we also value UnitedHealth Group, CVS Health Corporation, Elevance Health, Inc, The Cigna Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Humana Inc stock attractive at the current price?
The data as of Sep 29, 2026: price R$44.28, calculated fair value R$16.81 (−62%), Quality Score 55/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of H1UM34 calculated?
We run Humana Inc through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$16.81, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Humana Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Humana Inc (H1UM34)?
The closing price on Oct 2, 2026 was R$44.28. Our model-based fair value is R$16.81, about −62% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Humana Inc right now?
The price sits above even our optimistic bull case (R$27.11). The favourable scenario is already priced in. The model range is unusually wide (R$7.76 to R$27.11). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Humana Inc
How large is the market capitalisation of Humana Inc (H1UM34)?
The market capitalisation of Humana Inc is R$251B (≈ $48.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Humana Inc (H1UM34)?
The price-to-earnings ratio of Humana Inc is 41.0. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Humana Inc (H1UM34)?
The price-to-sales ratio of Humana Inc is 0.38 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Humana Inc (H1UM34)?
Earnings per share at Humana Inc are R$1.08 (price ÷ EPS = P/E 41.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Humana Inc (H1UM34)?
The dividend yield of Humana Inc is 8.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Humana Inc (H1UM34)?
The net margin of Humana Inc is 0.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Humana Inc (H1UM34)?
The return on equity (ROE) of Humana Inc is 6.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Humana Inc (H1UM34)?
On an EBIT basis the return on assets of Humana Inc is 7.2% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Humana Inc (H1UM34)?
The operating margin of Humana Inc is 4.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Humana Inc (H1UM34)?
Revenue at Humana Inc is growing +23.5% versus a year earlier (3y avg +11.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Humana Inc (H1UM34)?
Earnings per share at Humana Inc are growing −4.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Humana Inc (H1UM34) carry?
The net debt of Humana Inc is $8.2B (fiscal year 2025, ≈ 21.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.